1
|
Moquin SA, Simon O, Karuna R, Lakshminarayana SB, Yokokawa F, Wang F, Saravanan C, Zhang J, Day CW, Chan K, Wang QY, Lu S, Dong H, Wan KF, Lim SP, Liu W, Seh CC, Chen YL, Xu H, Barkan DT, Kounde CS, Sim WLS, Wang G, Yeo HQ, Zou B, Chan WL, Ding M, Song JG, Li M, Osborne C, Blasco F, Sarko C, Beer D, Bonamy GMC, Sasseville VG, Shi PY, Diagana TT, Yeung BKS, Gu F. NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Sci Transl Med 2021; 13:13/579/eabb2181. [PMID: 33536278 DOI: 10.1126/scitranslmed.abb2181] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Accepted: 01/13/2021] [Indexed: 12/12/2022]
Abstract
Dengue virus (DENV) is a mosquito-borne flavivirus that poses a threat to public health, yet no antiviral drug is available. We performed a high-throughput phenotypic screen using the Novartis compound library and identified candidate chemical inhibitors of DENV. This chemical series was optimized to improve properties such as anti-DENV potency and solubility. The lead compound, NITD-688, showed strong potency against all four serotypes of DENV and demonstrated excellent oral efficacy in infected AG129 mice. There was a 1.44-log reduction in viremia when mice were treated orally at 30 milligrams per kilogram twice daily for 3 days starting at the time of infection. NITD-688 treatment also resulted in a 1.16-log reduction in viremia when mice were treated 48 hours after infection. Selection of resistance mutations and binding studies with recombinant proteins indicated that the nonstructural protein 4B is the target of NITD-688. Pharmacokinetic studies in rats and dogs showed a long elimination half-life and good oral bioavailability. Extensive in vitro safety profiling along with exploratory rat and dog toxicology studies showed that NITD-688 was well tolerated after 7-day repeat dosing, demonstrating that NITD-688 may be a promising preclinical candidate for the treatment of dengue.
Collapse
Affiliation(s)
- Stephanie A Moquin
- Novartis Institutes for Biomedical Research, Emeryville, CA 94608, USA.,Novartis Institute for Tropical Diseases, Emeryville, CA 94608, USA
| | - Oliver Simon
- Novartis (Singapore) Pte Ltd, Singapore 117432, Singapore
| | - Ratna Karuna
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | | | - Fumiaki Yokokawa
- Novartis Institute for Tropical Diseases, Emeryville, CA 94608, USA
| | - Feng Wang
- Novartis Institutes for Biomedical Research, Emeryville, CA 94608, USA
| | - Chandra Saravanan
- Novartis Institutes for Biomedical Research, Translational Medicine: Preclinical Safety, Cambridge, MA 02139, USA
| | - Jin Zhang
- Novartis Institutes for Biomedical Research, Translational Medicine: Pharmacokinetics, East Hanover, NJ 07936, USA
| | - Craig W Day
- Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA
| | - Katherine Chan
- Novartis Institute for Tropical Diseases, Emeryville, CA 94608, USA
| | - Qing-Yin Wang
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | - Siyan Lu
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | - Hongping Dong
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | - Kah Fei Wan
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | - Siew Pheng Lim
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | - Wei Liu
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | - Cheah Chen Seh
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | - Yen-Liang Chen
- Novartis Institute for Tropical Diseases, Emeryville, CA 94608, USA
| | - Haoying Xu
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | - David T Barkan
- Novartis Institutes for Biomedical Research, Emeryville, CA 94608, USA
| | - Cyrille S Kounde
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | | | - Gang Wang
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | - Hui-Quan Yeo
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | - Bin Zou
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | - Wai Ling Chan
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | - Mei Ding
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | - Jae-Geun Song
- Novartis Institutes for Biomedical Research, Emeryville, CA 94608, USA
| | - Min Li
- Novartis Institutes for Biomedical Research, Emeryville, CA 94608, USA
| | - Colin Osborne
- Novartis Institute for Tropical Diseases, Emeryville, CA 94608, USA
| | - Francesca Blasco
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | | | - David Beer
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | | | - Vito G Sasseville
- Novartis Institutes for Biomedical Research, Translational Medicine: Preclinical Safety, Cambridge, MA 02139, USA
| | - Pei-Yong Shi
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
| | | | - Bryan K S Yeung
- Novartis Institute for Tropical Diseases, Singapore 138670, Singapore.
| | - Feng Gu
- Novartis Institute for Tropical Diseases, Emeryville, CA 94608, USA.
| |
Collapse
|
2
|
Hung K, Yokokawa F, Liu Y, Simon O, Zhang L, Lu P, Yeung BKS, Sarko C. Synthesis of a Potent Pan-Serotype Dengue Virus Inhibitor Having a Tetrahydrothienopyridine Core. Synlett 2020. [DOI: 10.1055/a-1323-4036] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
A synthesis of the first-in-class pan-serotype dengue virus inhibitor NITD-688 is presented. The Gewald reaction of N-(tert-butoxycarbonyl)-6,6-dimethylpiperidin-3-one with malononitrile and sulfur in the presence of l-proline as a catalyst gave tert-butyl 2-amino-3-cyano-6,6-dimethyl-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate. This was coupled with [4-(aminosulfonyl)phenyl]acetic acid by using propanephosphonic acid anhydride. A subsequent reductive alkylation with cyclohexanecarboxaldehyde gave NITD-688. Preliminary results of our attempts to control the regioselectivity of the Gewald synthesis of the 2-amino-3-cyanothiophene core are also presented.
Collapse
Affiliation(s)
- Kevin Hung
- Novartis Institute for Tropical Diseases
| | - Fumiaki Yokokawa
- Novartis Institute for Tropical Diseases
- Novartis Institutes for Tropical Diseases 10 Biopolis Road, no. 05-01, Chromos, Singapore 138670
| | | | - Oliver Simon
- Novartis Institutes for Tropical Diseases 10 Biopolis Road, no. 05-01, Chromos, Singapore 138670
| | - Lei Zhang
- Novartis Institute for Tropical Diseases
| | - Peichao Lu
- Novartis Institute for Tropical Diseases
| | - Bryan K. S. Yeung
- Novartis Institutes for Tropical Diseases 10 Biopolis Road, no. 05-01, Chromos, Singapore 138670
| | | |
Collapse
|
3
|
Chua ACY, Ong JJY, Malleret B, Suwanarusk R, Kosaisavee V, Zeeman AM, Cooper CA, Tan KSW, Zhang R, Tan BH, Abas SN, Yip A, Elliot A, Joyner CJ, Cho JS, Breyer K, Baran S, Lange A, Maher SP, Nosten F, Bodenreider C, Yeung BKS, Mazier D, Galinski MR, Dereuddre-Bosquet N, Le Grand R, Kocken CHM, Rénia L, Kyle DE, Diagana TT, Snounou G, Russell B, Bifani P. Robust continuous in vitro culture of the Plasmodium cynomolgi erythrocytic stages. Nat Commun 2019; 10:3635. [PMID: 31406175 PMCID: PMC6690977 DOI: 10.1038/s41467-019-11332-4] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Accepted: 06/28/2019] [Indexed: 01/19/2023] Open
Abstract
The ability to culture pathogenic organisms substantially enhances the quest for fundamental knowledge and the development of vaccines and drugs. Thus, the elaboration of a protocol for the in vitro cultivation of the erythrocytic stages of Plasmodium falciparum revolutionized research on this important parasite. However, for P. vivax, the most widely distributed and difficult to treat malaria parasite, a strict preference for reticulocytes thwarts efforts to maintain it in vitro. Cultivation of P. cynomolgi, a macaque-infecting species phylogenetically close to P. vivax, was briefly reported in the early 1980s, but not pursued further. Here, we define the conditions under which P. cynomolgi can be adapted to long term in vitro culture to yield parasites that share many of the morphological and phenotypic features of P. vivax. We further validate the potential of this culture system for high-throughput screening to prime and accelerate anti-P. vivax drug discovery efforts. Present understanding of Plasmodium vivax biology is hampered by its inability to grow in vitro. Here, the authors developed an in vitro culture of its simian counterpart, P. cynomolgi, which shares morphological and phenotypic similarities with P. vivax, initiating a new phase in vivax research.
Collapse
Affiliation(s)
- Adeline C Y Chua
- Singapore Immunology Network, A*STAR, Singapore, 138648, Singapore.,Department of Microbiology and Immunology, University of Otago, Dunedin, 9054, New Zealand.,Novartis Institute for Tropical Diseases, Singapore, 138670, Singapore
| | - Jessica Jie Ying Ong
- Department of Microbiology and Immunology, University of Otago, Dunedin, 9054, New Zealand.,Novartis Institute for Tropical Diseases, Singapore, 138670, Singapore
| | - Benoit Malleret
- Singapore Immunology Network, A*STAR, Singapore, 138648, Singapore.,Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119077, Singapore
| | - Rossarin Suwanarusk
- Singapore Immunology Network, A*STAR, Singapore, 138648, Singapore.,Department of Microbiology and Immunology, University of Otago, Dunedin, 9054, New Zealand
| | - Varakorn Kosaisavee
- Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119077, Singapore.,Department of Parasitology and Entomology, Faculty of Public Health, Mahidol University, Bangkok, 10400, Thailand
| | - Anne-Marie Zeeman
- Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, 2288, The Netherlands
| | - Caitlin A Cooper
- Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, 30602, USA
| | - Kevin S W Tan
- Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119077, Singapore
| | - Rou Zhang
- Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119077, Singapore
| | - Bee Huat Tan
- Novartis Institute for Tropical Diseases, Singapore, 138670, Singapore
| | | | - Andy Yip
- Novartis Institute for Tropical Diseases, Singapore, 138670, Singapore
| | - Anne Elliot
- Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, 30602, USA
| | - Chester J Joyner
- Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, Emory University, Atlanta, 30322, USA.,Emory Vaccine Center, Emory University, Atlanta, 30317, USA
| | - Jee Sun Cho
- Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119077, Singapore
| | - Kate Breyer
- Laboratory Animal Services, Scientific Operations, Novartis Institutes for Biomedical Research, East Hanover, 07936-1080, USA
| | - Szczepan Baran
- Laboratory Animal Services, Scientific Operations, Novartis Institutes for Biomedical Research, East Hanover, 07936-1080, USA
| | - Amber Lange
- Laboratory Animal Services, Scientific Operations, Novartis Institutes for Biomedical Research, East Hanover, 07936-1080, USA
| | - Steven P Maher
- Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, 30602, USA
| | - François Nosten
- Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, 63110, Thailand.,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine Research Building, University of Oxford Old Road Campus, Oxford, OX3 7FZ, UK
| | | | - Bryan K S Yeung
- Novartis Institute for Tropical Diseases, Singapore, 138670, Singapore
| | - Dominique Mazier
- Sorbonne Universités, UPMC Univ Paris 06, CR7, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, F-75013, France.,CIMI-Paris, INSERM, U1135, CNRS, Paris, F-75013, France
| | - Mary R Galinski
- Emory Vaccine Center, Emory University, Atlanta, 30317, USA.,Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, 30322, USA
| | - Nathalie Dereuddre-Bosquet
- CEA-Université Paris Sud 11-INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases (IMVA), IDMIT Department, IBJF, DRF, Fontenay-aux-Roses, 92265, France
| | - Roger Le Grand
- CEA-Université Paris Sud 11-INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases (IMVA), IDMIT Department, IBJF, DRF, Fontenay-aux-Roses, 92265, France
| | - Clemens H M Kocken
- Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, 2288, The Netherlands
| | - Laurent Rénia
- Singapore Immunology Network, A*STAR, Singapore, 138648, Singapore.,Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119077, Singapore
| | - Dennis E Kyle
- Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, 30602, USA
| | - Thierry T Diagana
- Novartis Institute for Tropical Diseases, Singapore, 138670, Singapore
| | - Georges Snounou
- Sorbonne Universités, UPMC Univ Paris 06, CR7, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, F-75013, France.,CIMI-Paris, INSERM, U1135, CNRS, Paris, F-75013, France.,CEA-Université Paris Sud 11-INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases (IMVA), IDMIT Department, IBJF, DRF, Fontenay-aux-Roses, 92265, France
| | - Bruce Russell
- Department of Microbiology and Immunology, University of Otago, Dunedin, 9054, New Zealand.
| | - Pablo Bifani
- Singapore Immunology Network, A*STAR, Singapore, 138648, Singapore. .,Novartis Institute for Tropical Diseases, Singapore, 138670, Singapore. .,Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119077, Singapore. .,Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, WC1E 7HT, UK.
| |
Collapse
|
4
|
Chua ACY, Ananthanarayanan A, Ong JJY, Wong JY, Yip A, Singh NH, Qu Y, Dembele L, McMillian M, Ubalee R, Davidson S, Tungtaeng A, Imerbsin R, Gupta K, Andolina C, Lee F, S-W Tan K, Nosten F, Russell B, Lange A, Diagana TT, Rénia L, Yeung BKS, Yu H, Bifani P. Hepatic spheroids used as an in vitro model to study malaria relapse. Biomaterials 2019; 216:119221. [PMID: 31195301 DOI: 10.1016/j.biomaterials.2019.05.032] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Accepted: 05/19/2019] [Indexed: 12/27/2022]
Abstract
Hypnozoites are the liver stage non-dividing form of the malaria parasite that are responsible for relapse and acts as a natural reservoir for human malaria Plasmodium vivax and P. ovale as well as a phylogenetically related simian malaria P. cynomolgi. Our understanding of hypnozoite biology remains limited due to the technical challenge of requiring the use of primary hepatocytes and the lack of robust and predictive in vitro models. In this study, we developed a malaria liver stage model using 3D spheroid-cultured primary hepatocytes. The infection of primary hepatocytes in suspension led to increased infectivity of both P. cynomolgi and P. vivax infections. We demonstrated that this hepatic spheroid model was capable of maintaining long term viability, hepatocyte specific functions and cell polarity which enhanced permissiveness and thus, permitting for the complete development of both P. cynomolgi and P. vivax liver stage parasites in the infected spheroids. The model described here was able to capture the full liver stage cycle starting with sporozoites and ending in the release of hepatic merozoites capable of invading simian erythrocytes in vitro. Finally, we showed that this system can be used for compound screening to discriminate between causal prophylactic and cidal antimalarials activity in vitro for relapsing malaria.
Collapse
Affiliation(s)
- Adeline C Y Chua
- Novartis Institute for Tropical Diseases, 138670, Singapore; Department of Microbiology and Immunology, University of Otago, Dunedin 9054, New Zealand; Singapore Immunology Network (SIgN), A*STAR, 138648, Singapore
| | | | - Jessica Jie Ying Ong
- Novartis Institute for Tropical Diseases, 138670, Singapore; Department of Microbiology and Immunology, University of Otago, Dunedin 9054, New Zealand
| | | | - Andy Yip
- Novartis Institute for Tropical Diseases, 138670, Singapore
| | | | | | - Laurent Dembele
- Novartis Institute for Tropical Diseases, 138670, Singapore; Université des Sciences, des Techniques et des Technologies de Bamako (USTTB); MRTC - DEAP - Faculty of Pharmacy, Bamako, Mali
| | - Michael McMillian
- Invitrocue Pte Ltd. 138667, Singapore; Department of Physiology, Yong Loo Lin School of Medicine, National University Health System, 117597, Singapore
| | - Ratawan Ubalee
- Department of Entomology, Armed Forces Research Institute of Medical Science (AFRIMS), Bangkok 10400,Thailand
| | - Silas Davidson
- Department of Entomology, Armed Forces Research Institute of Medical Science (AFRIMS), Bangkok 10400,Thailand
| | - Anchalee Tungtaeng
- Department of Veterinary Medicine, Armed Forces Research Institute of Medical Science (AFRIMS), Bangkok 10400,Thailand
| | - Rawiwan Imerbsin
- Department of Veterinary Medicine, Armed Forces Research Institute of Medical Science (AFRIMS), Bangkok 10400,Thailand
| | - Kapish Gupta
- Mechanobiology Institute, National University of Singapore, 117411, Singapore
| | - Chiara Andolina
- Shoklo Malaria Research Unit (SMRU), Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Fan Lee
- Institute of Bioengineering and Nanotechnology, A*STAR, 138669, Singapore
| | - Kevin S-W Tan
- Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 119077, Singapore
| | - François Nosten
- Shoklo Malaria Research Unit (SMRU), Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Bruce Russell
- Department of Microbiology and Immunology, University of Otago, Dunedin 9054, New Zealand
| | - Amber Lange
- Laboratory Animal Services, Scientific Operations, Novartis Institutes for Biomedical Research, East Hanover, NJ, 07936-1080, USA
| | | | - Laurent Rénia
- Singapore Immunology Network (SIgN), A*STAR, 138648, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 119077, Singapore
| | | | - Hanry Yu
- Invitrocue Pte Ltd. 138667, Singapore; Mechanobiology Institute, National University of Singapore, 117411, Singapore; Institute of Bioengineering and Nanotechnology, A*STAR, 138669, Singapore
| | - Pablo Bifani
- Novartis Institute for Tropical Diseases, 138670, Singapore; Singapore Immunology Network (SIgN), A*STAR, 138648, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 119077, Singapore.
| |
Collapse
|
5
|
Dembele L, Ang X, Chavchich M, Bonamy GMC, Selva JJ, Lim MYX, Bodenreider C, Yeung BKS, Nosten F, Russell BM, Edstein MD, Straimer J, Fidock DA, Diagana TT, Bifani P. The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites. Sci Rep 2017; 7:2325. [PMID: 28539634 PMCID: PMC5443816 DOI: 10.1038/s41598-017-02440-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Accepted: 04/11/2017] [Indexed: 11/23/2022] Open
Abstract
Malaria control and elimination are threatened by the emergence and spread of resistance to artemisinin-based combination therapies (ACTs). Experimental evidence suggests that when an artemisinin (ART)-sensitive (K13 wild-type) Plasmodium falciparum strain is exposed to ART derivatives such as dihydroartemisinin (DHA), a small population of the early ring-stage parasites can survive drug treatment by entering cell cycle arrest or dormancy. After drug removal, these parasites can resume growth. Dormancy has been hypothesized to be an adaptive physiological mechanism that has been linked to recrudescence of parasites after monotherapy with ART and, possibly contributes to ART resistance. Here, we evaluate the in vitro drug sensitivity profile of normally-developing P. falciparum ring stages and DHA-pretreated dormant rings (DP-rings) using a panel of antimalarial drugs, including the Plasmodium phosphatidylinositol-4-OH kinase (PI4K)-specific inhibitor KDU691. We report that while KDU691 shows no activity against rings, it is highly inhibitory against DP-rings; a drug effect opposite to that of ART. Moreover, we provide evidence that KDU691 also kills DP-rings of P. falciparum ART-resistant strains expressing mutant K13.
Collapse
Affiliation(s)
- L Dembele
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - X Ang
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - M Chavchich
- Department of Drug Evaluation, Australian Army Malaria Institute, Brisbane, QLD, 4051, Australia
| | - G M C Bonamy
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - J J Selva
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - M Yi-Xiu Lim
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - C Bodenreider
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - B K S Yeung
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - F Nosten
- Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.,Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - B M Russell
- Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand
| | - M D Edstein
- Department of Drug Evaluation, Australian Army Malaria Institute, Brisbane, QLD, 4051, Australia
| | - J Straimer
- Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY, 10032, USA
| | - D A Fidock
- Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY, 10032, USA.,Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, NY, 10032, USA
| | - T T Diagana
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore
| | - P Bifani
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, 138670, Singapore, Singapore. .,Department of Microbiology and Immunology Program, Yong Loo Lin School of Medicine, Life Sciences Institute, National University of Singapore, 119077, Singapore, Singapore.
| |
Collapse
|
6
|
Lim MYX, LaMonte G, Lee MC, Reimer C, Tan BH, Corey V, Tjahjadi BF, Chua A, Nachon M, Wintjens R, Gedeck P, Malleret B, Renia L, Bonamy GM, Ho PCL, Yeung BKS, Chow ED, Lim L, Fidock DA, Diagana TT, Winzeler EA, Bifani P. UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes. Nat Microbiol 2016; 1:16166. [PMID: 27642791 PMCID: PMC5575994 DOI: 10.1038/nmicrobiol.2016.166] [Citation(s) in RCA: 77] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2016] [Accepted: 08/08/2016] [Indexed: 01/08/2023]
Abstract
A molecular understanding of drug resistance mechanisms enables surveillance of the effectiveness of new antimicrobial therapies during development and deployment in the field. We used conventional drug resistance selection as well as a regime of limiting dilution at early stages of drug treatment to probe two antimalarial imidazolopiperazines, KAF156 and GNF179. The latter approach permits the isolation of low-fitness mutants that might otherwise be out-competed during selection. Whole-genome sequencing of 24 independently derived resistant Plasmodium falciparum clones revealed four parasites with mutations in the known cyclic amine resistance locus (pfcarl) and a further 20 with mutations in two previously unreported P. falciparum drug resistance genes, an acetyl-CoA transporter (pfact) and a UDP-galactose transporter (pfugt). Mutations were validated both in vitro by CRISPR editing in P. falciparum and in vivo by evolution of resistant Plasmodium berghei mutants. Both PfACT and PfUGT were localized to the endoplasmic reticulum by fluorescence microscopy. As mutations in pfact and pfugt conveyed resistance against additional unrelated chemical scaffolds, these genes are probably involved in broad mechanisms of antimalarial drug resistance.
Collapse
Affiliation(s)
- Michelle Yi-Xiu Lim
- Novartis Institute for Tropical Diseases, 138670 Singapore
- Department of Pharmacy, Faculty of Science, National University of Singapore, 119077 Singapore
| | - Gregory LaMonte
- Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA
| | - Marcus C.S. Lee
- Department of Microbiology & Immunology, Columbia University Medical Center, New York, New York 10032, USA
- Malaria Programme, Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, United Kingdom
| | - Christin Reimer
- Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA
| | - Bee Huat Tan
- Novartis Institute for Tropical Diseases, 138670 Singapore
| | - Victoria Corey
- Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA
| | - Bianca F. Tjahjadi
- Novartis Institute for Tropical Diseases, 138670 Singapore
- Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System
| | - Adeline Chua
- Novartis Institute for Tropical Diseases, 138670 Singapore
| | - Marie Nachon
- Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA
| | - René Wintjens
- Laboratory of Biopolymers and Supramolecular Nanomaterials, Faculty of Pharmacy, Université Libre de Bruxelles, Brussels, Belgium
| | - Peter Gedeck
- Novartis Institute for Tropical Diseases, 138670 Singapore
| | - Benoit Malleret
- Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System
- Singapore Immunology Network (SIgN), A*Star, Singapore
| | - Laurent Renia
- Singapore Immunology Network (SIgN), A*Star, Singapore
| | | | - Paul Chi-Lui Ho
- Department of Pharmacy, Faculty of Science, National University of Singapore, 119077 Singapore
| | | | - Eric D. Chow
- Center for Advanced Technology, Department of Biochemistry and Biophysics, University of California, San Francisco, California 94143, USA
| | - Liting Lim
- Novartis Institute for Tropical Diseases, 138670 Singapore
| | - David A. Fidock
- Department of Microbiology & Immunology, Columbia University Medical Center, New York, New York 10032, USA
- Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, New York 10032, USA
| | - Thierry T. Diagana
- Novartis Institute for Tropical Diseases, 138670 Singapore
- Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System
| | - Elizabeth A. Winzeler
- Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA
| | - Pablo Bifani
- Novartis Institute for Tropical Diseases, 138670 Singapore
- Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System
| |
Collapse
|
7
|
Zou B, Nagle A, Chatterjee AK, Leong SY, Tan LJ, Sim WLS, Mishra P, Guntapalli P, Tully DC, Lakshminarayana SB, Lim CS, Tan YC, Abas SN, Bodenreider C, Kuhen KL, Gagaring K, Borboa R, Chang J, Li C, Hollenbeck T, Tuntland T, Zeeman AM, Kocken CHM, McNamara C, Kato N, Winzeler EA, Yeung BKS, Diagana TT, Smith PW, Roland J. Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stages. ACS Med Chem Lett 2014; 5:947-50. [PMID: 25147620 DOI: 10.1021/ml500244m] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2014] [Accepted: 07/06/2014] [Indexed: 02/02/2023] Open
Abstract
Imidazopyridine 1 was identified from a phenotypic screen against P. falciparum (Pf) blood stages and subsequently optimized for activity on liver-stage schizonts of the rodent parasite P. yoelii (Py) as well as hypnozoites of the simian parasite P. cynomolgi (Pc). We applied these various assays to the cell-based lead optimization of the imidazopyrazines, exemplified by 3 (KAI407), and show that optimized compounds within the series with improved pharmacokinetic properties achieve causal prophylactic activity in vivo and may have the potential to target the dormant stages of P. vivax malaria.
Collapse
Affiliation(s)
- Bin Zou
- Novartis Institute for Tropical Diseases, 10 Biopolis Road #05-01 Chromos, 138670 Singapore
| | - Advait Nagle
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| | - Arnab K. Chatterjee
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| | - Seh Yong Leong
- Novartis Institute for Tropical Diseases, 10 Biopolis Road #05-01 Chromos, 138670 Singapore
| | - Liying Jocelyn Tan
- Novartis Institute for Tropical Diseases, 10 Biopolis Road #05-01 Chromos, 138670 Singapore
| | - Wei Lin Sandra Sim
- Novartis Institute for Tropical Diseases, 10 Biopolis Road #05-01 Chromos, 138670 Singapore
| | - Pranab Mishra
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| | - Prasuna Guntapalli
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| | - David C. Tully
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| | | | - Chek Shik Lim
- Novartis Institute for Tropical Diseases, 10 Biopolis Road #05-01 Chromos, 138670 Singapore
| | - Yong Cheng Tan
- Novartis Institute for Tropical Diseases, 10 Biopolis Road #05-01 Chromos, 138670 Singapore
| | - Siti Nurdiana Abas
- Novartis Institute for Tropical Diseases, 10 Biopolis Road #05-01 Chromos, 138670 Singapore
| | - Christophe Bodenreider
- Novartis Institute for Tropical Diseases, 10 Biopolis Road #05-01 Chromos, 138670 Singapore
| | - Kelli L. Kuhen
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| | - Kerstin Gagaring
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| | - Rachel Borboa
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| | - Jonathan Chang
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| | - Chun Li
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| | - Thomas Hollenbeck
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| | - Tove Tuntland
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| | - Anne-Marie Zeeman
- Department of Parasitology, Biomedical Primate Research Centre, 2280 GH Rijswijk, The Netherlands
| | - Clemens H. M. Kocken
- Department of Parasitology, Biomedical Primate Research Centre, 2280 GH Rijswijk, The Netherlands
| | - Case McNamara
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| | - Nobutaka Kato
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| | - Elizabeth A. Winzeler
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
- Department of Pediatrics, School of Medicine, University of California, San Diego, California 92093, United States
| | - Bryan K. S. Yeung
- Novartis Institute for Tropical Diseases, 10 Biopolis Road #05-01 Chromos, 138670 Singapore
| | - Thierry T. Diagana
- Novartis Institute for Tropical Diseases, 10 Biopolis Road #05-01 Chromos, 138670 Singapore
| | - Paul W. Smith
- Novartis Institute for Tropical Diseases, 10 Biopolis Road #05-01 Chromos, 138670 Singapore
| | - Jason Roland
- Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States
| |
Collapse
|
8
|
Spillman NJ, Allen RJW, McNamara CW, Yeung BKS, Winzeler EA, Diagana TT, Kirk K. Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe 2013; 13:227-37. [PMID: 23414762 PMCID: PMC3574224 DOI: 10.1016/j.chom.2012.12.006] [Citation(s) in RCA: 147] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2012] [Revised: 10/28/2012] [Accepted: 12/20/2012] [Indexed: 01/06/2023]
Abstract
The malaria parasite Plasmodium falciparum establishes in the host erythrocyte plasma membrane new permeability pathways that mediate nutrient uptake into the infected cell. These pathways simultaneously allow Na(+) influx, causing [Na(+)] in the infected erythrocyte cytosol to increase to high levels. The intraerythrocytic parasite itself maintains a low cytosolic [Na(+)] via unknown mechanisms. Here we present evidence that the intraerythrocytic parasite actively extrudes Na(+) against an inward gradient via PfATP4, a parasite plasma membrane protein with sequence similarities to Na(+)-ATPases of lower eukaryotes. Mutations in PfATP4 confer resistance to a potent class of antimalarials, the spiroindolones. Consistent with this, the spiroindolones cause a profound disruption in parasite Na(+) homeostasis, which is attenuated in parasites bearing resistance-conferring mutations in PfATP4. The mutant parasites also show some impairment of Na(+) regulation. Taken together, our results are consistent with PfATP4 being a Na(+) efflux ATPase and a target of the spiroindolones.
Collapse
Affiliation(s)
- Natalie J Spillman
- Research School of Biology, The Australian National University, Canberra, ACT 0200, Australia
| | | | | | | | | | | | | |
Collapse
|
9
|
Zou B, Yap P, Sonntag LS, Leong SY, Yeung BKS, Keller TH. Mechanistic study of the spiroindolones: a new class of antimalarials. Molecules 2012; 17:10131-41. [PMID: 22922283 PMCID: PMC6268731 DOI: 10.3390/molecules170910131] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2012] [Revised: 08/11/2012] [Accepted: 08/16/2012] [Indexed: 11/16/2022] Open
Abstract
During the synthesis of the new antimalarial drug candidate NITD609, a high degree of diastereoselectivity was observed in the Pictet-Spengler reaction. By isolating both the 4E and 4Z imine intermediates, a systematic mechanistic study of the reaction under both kinetic and thermodynamic conditions was conducted. This study provides insight into the source of the diastereoselectivity for this important class of compounds.
Collapse
Affiliation(s)
- Bin Zou
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, Singapore
- Author to whom correspondence should be addressed; ; Tel.: +65-6722-2921; Fax: +65-6722-2918
| | - Peiling Yap
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, Singapore
| | | | - Seh Yong Leong
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, Singapore
| | - Bryan K. S. Yeung
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, #05-01 Chromos, Singapore
| | - Thomas H. Keller
- Experimental Therapeutics Centre, 31 Biopolis Drive, #03-01 Nanos, Singapore;
| |
Collapse
|
10
|
Chatterjee AK, Yeung BKS. Back to the future: lessons learned in modern target-based and whole-cell lead optimization of antimalarials. Curr Top Med Chem 2012; 12:473-83. [PMID: 22242845 PMCID: PMC3355380 DOI: 10.2174/156802612799362977] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2011] [Revised: 11/09/2011] [Accepted: 11/17/2011] [Indexed: 11/22/2022]
Abstract
Antimalarial drug discovery has historically benefited from the whole-cell (phenotypic) screening approach to identify lead molecules in the search for new drugs. However over the past two decades there has been a shift in the pharmaceutical industry to move away from whole-cell screening to target-based approaches. As part of a Wellcome Trust and Medicines for Malaria Venture (MMV) funded consortium to discover new blood-stage antimalarials, we used both approaches to identify new antimalarial chemotypes, two of which have progressed beyond the lead optimization phase and display excellent in vivo efficacy in mice. These two advanced series were identified through a cell-based optimization devoid of target information and in this review we summarize the advantages of this approach versus a target-based optimization. Although the each lead optimization required slightly different medicinal chemistry strategies, we observed some common issues across the different the scaffolds which could be applied to other cell based lead optimization programs.
Collapse
Affiliation(s)
- Arnab K Chatterjee
- Genomics Institute, Novartis Research Foundation, San Diego, CA 92121, USA.
| | | |
Collapse
|
11
|
Rottmann M, McNamara C, Yeung BKS, Lee MCS, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, González-Páez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT. Spiroindolones, a potent compound class for the treatment of malaria. Science 2010; 329:1175-80. [PMID: 20813948 DOI: 10.1126/science.1193225] [Citation(s) in RCA: 902] [Impact Index Per Article: 64.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Recent reports of increased tolerance to artemisinin derivatives--the most recently adopted class of antimalarials--have prompted a need for new treatments. The spirotetrahydro-beta-carbolines, or spiroindolones, are potent drugs that kill the blood stages of Plasmodium falciparum and Plasmodium vivax clinical isolates at low nanomolar concentration. Spiroindolones rapidly inhibit protein synthesis in P. falciparum, an effect that is ablated in parasites bearing nonsynonymous mutations in the gene encoding the P-type cation-transporter ATPase4 (PfATP4). The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model.
Collapse
Affiliation(s)
- Matthias Rottmann
- Swiss Tropical and Public Health Institute, Parasite Chemotherapy, CH-4002 Basel, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Yeung BKS, Zou B, Rottmann M, Lakshminarayana SB, Ang SH, Leong SY, Tan J, Wong J, Keller-Maerki S, Fischli C, Goh A, Schmitt EK, Krastel P, Francotte E, Kuhen K, Plouffe D, Henson K, Wagner T, Winzeler EA, Petersen F, Brun R, Dartois V, Diagana TT, Keller TH. Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem 2010; 53:5155-64. [PMID: 20568778 PMCID: PMC6996867 DOI: 10.1021/jm100410f] [Citation(s) in RCA: 318] [Impact Index Per Article: 22.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
![]()
The antiplasmodial activity of a series of spirotetrahydro β-carbolines is described. Racemic spiroazepineindole (1) was identified from a phenotypic screen on wild type Plasmodium falciparum with an in vitro IC50 of 90 nM. Structure−activity relationships for the optimization of 1 to compound 20a (IC50 = 0.2 nM) including the identification of the active 1R,3S enantiomer and elimination of metabolic liabilities is presented. Improvement of the pharmacokinetic profile of the series translated to exceptional oral efficacy in the P. berghei infected malaria mouse model where full cure was achieved in four of five mice with three daily doses of 30 mg/kg.
Collapse
Affiliation(s)
- Bryan K S Yeung
- Novartis Institute for Tropical Diseases, 10 Biopolis Road, no. 05-01 Chromos, Singapore 138670.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Yeung BKS, Tse WC, Boger DL. Determination of binding affinities of triplex forming oligonucleotides using a fluorescent intercalator displacement (FID) assay. Bioorg Med Chem Lett 2004; 13:3801-4. [PMID: 14552783 DOI: 10.1016/j.bmcl.2003.07.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The binding affinities of several triplex forming oligonucleotides were determined using a fluorescent intercalator displacement (FID) assay.
Collapse
Affiliation(s)
- Bryan K S Yeung
- Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
| | | | | |
Collapse
|
14
|
Adamski-Werner SL, Yeung BKS, Miller-Deist LA, Petillo PA. Gram-scale syntheses of the (1→3)-linked and (1→4)-linked hyaluronan disaccharides. Carbohydr Res 2004; 339:1255-62. [PMID: 15113662 DOI: 10.1016/j.carres.2004.03.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2003] [Accepted: 03/02/2004] [Indexed: 11/22/2022]
Abstract
The first gram-scale syntheses of two hyaluronan disaccharides are described. Construction of the (1-->4)-linked disaccharide 12 was achieved in 12% overall yield using 2,3-bis-dimethyl acetal protection in combination with chlorosilane-induced carbamate cleavage methodologies. The uronic acid functionality was installed using TEMPO oxidation with NaOCl as the hypochlorite source. The (1-->3)-linked disaccharide 18 was achieved in 7% overall yield utilizing acetonide protection in addition to the chlorosilane-induced carbamate cleavage methodology and the TEMPO oxidation.
Collapse
Affiliation(s)
- Sara L Adamski-Werner
- Department of Chemistry, University of Illinois, 600 S. Mathews Ave., Urbana, IL 61801, USA
| | | | | | | |
Collapse
|
15
|
Abstract
The synthesis of the alkylating subunit of the DNA cross-linking agent, isochrysohermidin (2), and its subsequent incorporation into conjugates with distamycin A (1) are described. The DNA binding properties of these agents were compared to that of distamycin A, using a fluorescence intercalator displacement (FID) assay.
Collapse
Affiliation(s)
- Bryan K S Yeung
- Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
| | | |
Collapse
|
16
|
Nasu SS, Yeung BKS, Hamann MT, Scheuer PJ, Kelly-Borges M, Goins K. Puupehenone-related metabolites from two Hawaiian sponges, Hyrtios spp. J Org Chem 2002. [DOI: 10.1021/jo00127a039] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Nakao Y, Yeung BKS, Yoshida WY, Scheuer PJ, Kelly-Borges M. Kapakahine B, a cyclic hexapeptide with an .alpha.-carboline ring system from the marine sponge Cribrochalina olemda. J Am Chem Soc 2002. [DOI: 10.1021/ja00136a026] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Yeung BKS, Nakao Y, Kinnel RB, Carney JR, Yoshida WY, Scheuer PJ, Kelly-Borges M. The Kapakahines, Cyclic Peptides from the Marine Sponge Cribrochalina olemda. J Org Chem 1996; 61:7168-7173. [PMID: 11667621 DOI: 10.1021/jo960725e] [Citation(s) in RCA: 71] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Four cyclic peptides, kapakahines A-D, were isolated from the marine sponge Cribrochalina olemda. Their structures including complete stereochemistry were elucidated by spectral analysis and chemical degradation. The unique structural feature of these peptides is the lack of an amide linkage between two tryptophan residues. Instead the ring is closed by a bond from the indole nitrogen of Trp-1 to the beta-carbon of Trp-2.
Collapse
Affiliation(s)
- Bryan K. S. Yeung
- Harbor Branch Oceanographic Institution, Inc.,(2) 5600 North U.S. 1, Fort Pierce, Florida 34936
| | | | | | | | | | | | | |
Collapse
|